Abstract Body

Background: The HIV auxiliary protein known as viral infectivity factor (Vif) enables HIV to overcome cellular APOBEC host-defense factors by binding to these proteins as a substrate receptor, thereby ensuring their ubiquitination and degradation through the 26S proteasome. Vif-Vif interaction through the PPLP domain has been shown to be ‘druggable’ in living cells using peptide mimetics. Disruption of Vif dimers inhibited live virus in spreading infection assays by protecting A3G from Vif-dependent degradation and enabled A3G incorporate in viral particles (Miller et al., (2007) Retrovirology 4:81-91). Methodology: Live cell FRET for Vif dimerization in high throughput screening together with medicinal chemistry have identifying a small molecule Vif dimerization antagonist (SMVDA002-16) with low cytotoxicity and nM antiviral efficacy. Results: Inhibition of HIV infection showed strict dependence on the expression of Vif and APOBEC3G. SMVDA002-16 enabled A3G antiviral activity by protecting A3G from Vif-dependent degradation, enhanced virion incorporation of A3G and inhibited viral replication. Analysis of integrated viral genomes for mutations in the pol gene in these studies following 48 hrs and 7 days of infection revealed extensive G to A hypermutation with numerous sense and nonsense codon changes. Infection of PBMC by 17 HIV isolates covering the 9 major HIV subtypes along with 8 drug resistant HIV strains was suppressed following a single dose of SMVDA002-16. Conclusions: Compounds that bind to Vif and inhibit Vif dimerization can be effective antivirals due to their ability to enable APOBEC3G host defense. There is a clear imperative to aggressively pursue this target for first-in-class therapeutics, prophylaxis and a potential functional cure.